BioTuesdays
Cellectar Biosciences
Markets

Brookline starts Cellectar Biosciences at buy; PT $6

Brookline Capital Markets launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and price target of $6. The stock closed at $2.14 on July 29. Cellectar has a unique cancer target delivery platform...

July 30, 2019
Markets

Brookline starts Progenics Pharma at buy; PT $10

Brookline Capital Markets initiated coverage of Progenics Pharmaceuticals (NASDAQ:PGNX) with a “buy” rating and $10 price target. The stock closed at $5.25 on July 29. “We expect that Progenics is well poised to ramp up...

July 30, 2019
Heat Biologics
Markets

Brookline starts Heat Biologics at buy; PT $8

Brookline Capital Markets launched coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $8 price target. The stock closed at 52 cents on July 29. Heat Biologics has cell-therapy platforms called ImPACT and...

July 30, 2019
Markets

Brookline starts Veru at buy; PT $12

Brookline Capital Markets initiated coverage of Veru (NASDAQ:VERU) with a “buy” rating and $12 price target. The stock closed at $2.23 on July 29. “In our view, VERU-111 and zuclomiphene have potential to be value...

July 30, 2019
KalVista Pharmaceuticals Logo
Markets

SVB Leerink starts Kalvista Pharma at OP; PT $31

SVB Leerink initiated coverage of Kalvista Pharmaceuticals (NASDAQ:KALV) with an “outperform” rating and $31 price target. The stock closed at $16.92 on July 26. Kalvista is creating a new generation of small molecule...

July 29, 2019
Celsion
Markets

Brookline starts Celsion at buy; PT $9

Brookline Capital Markets launched coverage of Celsion (NASDAQ:CLSN) with a “buy” rating and $9 price target. The stock closed at $1.79 on July 25. Celsion is focused on clinical-stage oncology products and platform...

July 26, 2019
Onconova Logo
Markets

Noble starts Onconova Therapeutics at OP; PT $12

Noble Financial launched coverage of Onconova Therapeutics (NASDAQ:ONTX) with an “outperform” rating and $12 price target. The stock was quoted at $2.62 at midday on July 25. Onconova is currently focused on completing...

July 25, 2019
Markets

Brookline starts Chiasma at buy; PT $15

Brookline Capital Markets initiated coverage of Chiasma (NASDAQ:CHMA) with a “buy” rating and $15 price target. Chiasma is developing Mycapssa as potential maintenance treatment for adults with acromegaly, a hormonal...

July 25, 2019
Vanda Pharmaceuticals
Markets

Stifel cuts Vanda Pharma to hold; PT to $17 from $26

Stifel downgraded Vanda Pharmaceuticals (NASDAQ:VNDA) to “hold” from “buy” and cut its price target to $17 from $26 after a deeper look into a FDA lawsuit against the company, its pipeline and execution risk. The stock...

July 25, 2019
Viveve Medical Logo
Markets

Stifel cuts Viveve Medical to hold; PT to $1 from $3

Stifel downgraded Viveve Medical (NASDAQ:VIVE) to “hold” from “buy” and lowered its price target to $1 from $3 after the company’s LIBERATE-International trial for stress urinary incontinence (SUI) missed its primary...

July 23, 2019
Markets

WB starts Change Healthcare at OP

William Blair launched coverage of Change Healthcare (NASDAQ:CHNG) with an “outperform” rating. The stock closed at $13.50 on July 19. Change Healthcare is a leading healthcare technology platform provider, offering...

July 22, 2019
Precision Biosciences
Markets

HCW starts Precision BioSciences at buy; PT $21

H.C. Wainwright initiated coverage of Precision BioSciences (NASDAQ:DTIL) with a “buy” rating and $21 price target. The stock closed at $13.76 on July 15. Precision is one of the early adopters of a potential paradigm...

July 16, 2019
Markets

Roth starts Akero Therapeutics at buy; PT $34

Roth Capital Partners initiated coverage of Akero Therapeutics (NASDAQ:AKRO) with a “buy” rating and price target of $34. The stock closed at $19.88 on July 12. “Although Akero’s lead asset, AKR-001 (a FGF21...

July 15, 2019
Syros-Logo
Markets

Roth resumes coverage of Syros Pharma at buy; PT $17

Roth Capital Partners resumed coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “buy” rating and $17 price target. The stock was quoted at $8.49 in afternoon trading on July 12. Syros was co-founded by ARCH Venture...

July 12, 2019
rhythm pharmaceuticals
Markets

Stifel ups Rhythm Pharma to buy; PT held at $34

Stifel upgraded Rhythm Pharmaceuticals (NASDAQ:RYTM) to “buy” from “hold” but maintained its price target at $34, saying the stock is at an attractive entry point ahead of near-term Phase 3 results. The stock closed at...

July 12, 2019
maxim Group Logo
Markets

Maxim cuts PTs on five biotech stocks

Maxim Group reduced price targets for five biotech stocks, citing data troughs, financing conditions and political factors, which may be further compounded by a lack of catalysts and increasing operating expenses...

July 9, 2019